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BACKGROUND: About 1–5% of cancer patients suffer from significant normal tissue reactions as a result of radiotherapy (RT). It is not
possible at this time to predict how most patients’ normal tissues will respond to RT. DNA repair dysfunction is implicated in
sensitivity to RT particularly in genes that mediate the repair of DNA double-strand breaks (DSBs). Phosphorylation of histone H2AX
(phosphorylated molecules are known as gH2AX) occurs rapidly in response to DNA DSBs, and, among its other roles, contributes
to repair protein recruitment to these damaged sites. Mammalian cell lines have also been crucial in facilitating the successful cloning
of many DNA DSB repair genes; yet, very few mutant cell lines exist for non-syndromic clinical radiosensitivity (RS).
METHODS: Here, we survey DNA DSB induction and repair in whole cells from RS patients, as revealed by gH2AX foci assays,
as potential predictive markers of clinical radiation response.
RESULTS: With one exception, both DNA focus induction and repair in cell lines from RS patients were comparable with controls.
Using gH2AX foci assays, we identified a RS cancer patient cell line with a novel ionising radiation-induced DNA DSB repair defect;
these data were confirmed by an independent DNA DSB repair assay.
CONCLUSION: gH2AX focus measurement has limited scope as a pre-RT predictive assay in lymphoblast cell lines from RT patients;
however, the assay can successfully identify novel DNA DSB repair-defective patient cell lines, thus potentially facilitating the
discovery of novel constitutional contributions to clinical RS.
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Radiotherapy (RT) is one of the main strategies for cancer
treatment, and is a prime contributor to cancer patient survival
and loco-regional tumour control (Morgan et al, 2004). Radio-
therapy dose intensities are typically selected to avoid an
unacceptable frequency of severe adverse normal tissue reactions
and hence, most patients could potentially tolerate RT dose
escalation. This is expected to significantly improve loco-regional
cancer control and patient survival. Identification of predictive
markers of radiosensitivity (RS) may enable individualisation of
RT, which till date has not been achieved in clinical practice.
Many assays with the goal of predicting RS in normal tissues
before RT have been attempted, with modest success. Assays that
have shown promise include colony survival assays (Brock et al,
1995; West et al, 1998), chromosomal aberration frequency
(Neubauer et al, 1997, 2002; Distel et al, 2006), comet assay
(Brammer et al, 2001), DNA damage and repair based on pulsed-
field gel electrophoresis (PFGE) (Wurm et al, 1994; McKay and
Kefford, 1995; Zhou et al, 1998), micronucleus assay (Nachtrab
et al, 1998; Sprung et al, 2005), telomere length (McIlrath et al,
2001; Sprung et al, 2008), SNP analysis (Severin et al, 2001; Gurska
et al, 2007; Wilding et al, 2007; Alsner et al, 2008), DNA end
binding complexes (Ismail et al, 2004) and transcriptional
profiling (Rieger et al, 2004; Svensson et al, 2006; Sprung et al,
in preparation). Thus, many potential endpoints exist, most of
which have been partially successful in identifying clinical RS.
Given the probable diversity in molecular pathogenesis of RS
and the results from these cellular biophysical and molecular
assays, most assays will probably be useful only for a minority
of patients. A combination of selected assays may ultimately
be successful.
Cancer patients are exposed to ionising radiation (IR) during RT
treatment, which causes several types of cellular damage, of which
DNA double-strand break (DSB) damage is the most significant,
as DSBs can result in clastogenesis, mutagenesis and cell death
by diverse mechanisms, including mitotic catastrophe, deletions
and/or mutations (Sprung et al, 2002). An early event in DNA DSB
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repair is the phosphorylation of histone H2AX (gH2AX) at the DSB
site, which in less than an hour encompasses a region spanning
several megabases (Rogakou et al, 1998), forming a light-
microscopically visible focus (Rogakou et al, 1999). H2AX protein
is phosphorylated on the carboxy terminal at serine 139 by DNA-
PKcs, ATM or ATR (Rogakou et al, 1998; Paull et al, 2000; Burma
and Chen, 2004). The number of DSBs can be directly determined
by the number of foci present in the cell shortly after DNA damage
(Sedelnikova et al, 2002). Cells either deficient in or with
mutations in the large signalling protein kinases that phospho-
rylate H2AX are typified by radiation sensitivity, DNA repair
defects and genomic instability (Shiloh, 2001). Phosphorylation of
H2AX at the site of a DSB induces chromatin remodelling, further
amplifying the signal response cascade and resulting in down-
stream events such as cell cycle arrest, checkpoint activation and
cell death (Shiloh, 2003; McGowan and Russell, 2004). gH2AX has
been found to recruit various repair factors to the site of DNA
damage, has an anchoring function and also retains the broken
chromosomal ends in close proximity (Bassing and Alt, 2004).
Although initial migration of various signalling and repair factors
to DSBs occurs very rapidly (Nelms et al, 1998), accumulation into
visible IR-induced H2AX foci becomes apparent long after DNA
damage, with co-localisation of 53bp1, Mdc1, Mre11, Rad50, Nbs1,
Rad17 and Brca1 to foci developing afterwards (Paull et al, 2000;
Stucki and Jackson, 2006; Spycher et al, 2008). gH2AX-deficient
cell lines can maintain DSB-induced signalling, and gH2AX
formation is not necessary for non-homologous end joining and
homologous recombination-mediated DNA DSB repair, but these
processes have decreased efficiency in such cells (Petersen et al,
2001; Bassing et al, 2002; Celeste et al, 2003).
The half-life of gH2AX foci after DNA damage is approximately
2–7 h in various cell types (MacPhail et al, 2003; Bouquet et al,
2006). Focus loss may be because of non-repair events that
contribute to assay background. Although selection of appropriate
controls can potentially overcome this issue, they may have an
impact on assay sensitivity. Bouquet et al formally documented, as
would be logical to expect, that loss of gH2AX foci can be because
of dephosphorylation. Recent genetic and biochemical approaches
have shown the role of phosphatases in the removal of the gH2AX
phosphate group at DSB sites (Chowdhury et al, 2005; Keogh et al,
2006). Another possibility is gH2AX exchange, which involves
replacement of phosphorylated H2AX with an unphosphorylated
H2AX, for which there is evidence in yeast and Drosophila (Kusch
et al, 2004; Svetlova et al, 2007). It has been proposed that the
signal for gH2AX depletion is completion of a critical DNA repair
step.
Before this study, gH2AX was approved as a marker of DNA
damage and repair and was considered likely to be an improved
candidate predictive assay, as it is associated with DSBs in their
native and post-irradiation modulated chromatin and is a main
lesion following radiation, with foci being easily visualised and
quantitated. In addition gH2AX foci are assayed in situ and can be
observed in a reasonable time frame following IR treatment, which
is an important clinical requirement for a predictive assay. As
there is a lag time to full completion of DNA DSB repair, as
measured by gH2AX foci assays, it is believed that the recovery of
non-phosphorylated H2AX must be associated with factors other
than just the rejoining of broken DNA, such as proper chromatin
organisation (Olive and Banath 2004).
gH2AX foci kinetics have been examined in a number of RS
cellular models. Tumour cell lines of lower RS showed slower rates
of gH2AX depletion than more RS cell lines (Banath et al, 2004;
Olive and Banath, 2004; Taneja et al, 2004). Likewise, H2AX
phosphorylation depletion was found to be slower in cells with
higher intrinsic RS (Olive and Banath, 2004). Increased cellular RS
in 18 tumour cell lines, as measured by clonogenic survival,
correlated with increased residual gH2AX foci (Klokov et al, 2006)
and other previous DSB repair methods. However, not all studies
have found correlations between gH2AX foci and RS. For example,
no such correlation was observed in primary fibroblasts from
acute RS vs control patients (Mahrhofer et al, 2006). Moreover, no
correlation of gH2AX foci kinetics was observed in peripheral
blood mononuclear cells from prostate cancer patients with late
effects (Olive et al, 2008).
Quantification of gH2AX foci using immunocytochemistry
(ICC) is the most sensitive method, with a detection potential of
a single focus within the nucleus (Qvarnstro¨m et al, 2004). Here we
use gH2AX ICC methods and our collection of lymphoblast cell
lines (LCLs) derived from severe RS patients (both acute- and late-
effect cases), using molecular-based assays focusing on DNA
breakage and repair in an attempt to identify individuals who show
abnormal phenotypes.
MATERIALS AND METHODS
Cell culture
Cancer patient lymphocyte cells were isolated from individuals
who did and did not have a severe reaction to RT, and LCLs were
derived as previously described (Neitzel, 1986; Severin et al, 2001;
Sprung et al, 2005). Radiosensitive LCLs were derived from
patients who had been classified as Radiotherapy Oncology Group
(RTOG) 3 or 4; LCLs classified as RTOG 0-1 were selected for use
as controls. The ataxia telangiectasia (AT)-deficient LCLs were
derived in the same manner. The ligase IV human knock-out LCLs
were derived from a Nalm6 cell line as described previously (Distel
et al, 2003; Sprung et al, 2008). The clinicopathological patient
characteristics are presented in Table 1. Lymphoblast cell lines
were grown in RPMI-1640, 10% FBS and 20 mgml1 of gentamicin
in a humidified 5% CO2 environment.
cH2AX foci immunofluorescence
After two washes in phosphate-buffered saline (PBS: 137mM NaCl,
2.7mM KCl, 10mM Na2HPO4, 2mM KH2PO4), LCLs were plated at a
concentration of 7 105 cells per ml in fresh RPMI. The cell lines
were coded, and so the results were obtained without knowledge of
the RS status of the patient from whom they were derived. Cells
were exposed to 0 Gy, 1, 2 or 4Gy of gamma radiation from a 137Cs
source at a dose rate of 0.62Gymin1 on ice and then placed at
371C for 1 h. Aliquots of 0.7 105 cells were cytospun for 5min at
500 r.p.m. onto polysine slides (Menzel-Glaser, Braunschweig,
Germany). The slides were fixed for 5min with 4% paraformalde-
hyde (Sigma-Aldrich, St Louis, MO, USA), rinsed with PBS, and
then the cells were permeabilised for 5min in 0.1% Triton X-100
followed by three 5-min PBS washes. Slides were treated thrice for
10min in a blocking solution of 1% bovine serum albumin (BSA)
(Invitrogen, Molecular Probes, Eugene, OR, USA). Mouse anti-
gH2AX antibody (Upstate, Lake Placid, NY, USA) was added
(1 : 500 in 1% BSA) and incubated for 2 h in a dark room-
temperature-humidified environment. Slides were then exposed to
a secondary goat anti-mouse antibody (1 : 500 in PBS) conjugated
with Alexa-488 (Molecular Probes) and incubated for 1 h in the
dark room-temperature-humidified environment. Slides were
rinsed thrice in PBS and stained with 0.2mgml1 of 40,6-
diamidino-2-phenylindole (DAPI, Sigma). Using an Olympus
microscope with an  60 oil immersion objective (Olympus
IX81, Tokyo, Japan), gH2AX foci images were acquired using a
constant exposure time of 500ms. Eight to ten z-sections with a
0.5-mm step size were deconvoluted to obtain gH2AX foci images
for counting using Metamorph (Molecular Probes), by applying
morphological filters, Top-hat and H-dome with constant thresh-
olds set at 40 (low) to 1500 (high). Foci count primary data are
presented in Supplementary Table S1. Blood collection from patients
was approved by the Peter MacCallum Cancer Centre Ethics
Committee and informed consent was obtained from all patients.
cH2AX response in radiosensitive cancer patient cells
RS Vasireddy et al
1512
British Journal of Cancer (2010) 102(10), 1511 – 1518 & 2010 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
PFGE assay
3H-thymidine was added to log-phase LCLs and the cells were
allowed to grow for an additional 24 h at 371C. Lymphoblast cell
lines were washed twice with PBS solution (1.4 M NaCl, 0.02 M KCl,
0.05 M Na2HPO4 and 0.02 M NaH2PO4). Approximately 4 105 cells
per ml from each cell line were irradiated at 40Gy on ice, and then
transferred to a 371C incubator for time points of 0, 30, 60, 120 and
240min. At these time points, aliquots of 2 105 cells were mixed
in 0.8% low-melting-point (LMP) agarose diluted in PBS, and 50 ml
plugs were prepared and stored at 41C for 20min until lysis. Lysis
was carried out using ice-cold lysis buffer (2% sarkosyl, 1mgml1
proteinase K, Promega, Madison, WI, USA, in 400mM Na2EDTA,
pH 8) for 1 h at 41C and then incubated at 501C for 20 h. Plugs were
washed thrice for 30min in 0.1 M EDTA and equilibrated in
running buffer (45mM Tris base, 45mM boric acid, 1mM
Na2EDTA, pH 8 (TBE)) for 30min before PFGE. 0.8% gels were
prepared and run in 0.5 TBE gel running buffer. Plugs
were sealed with 0.8% LMP agarose and placed in a Gene
Navigator (Pharmacia Biotech, Uppsala, Sweden) PFGE unit.
Electrophoresis was performed at 6.5 V cm1 at 141C, with a pulse
rate of 5 and 8 s for 3 h each. To view the fraction of DNA released
into the gel, the gel was stained using SYBR Gold (Invitrogen,
Carlsbad, CA, USA) and imaged using a Molecular Imager FX
(Bio-Rad, Hercules, CA, USA). The fraction of DNA released from
the gels was cut using SYBR gold stain as a template, and solubilised
in concentrated HCl, mixed with a liquid scintillation cocktail
(Beckman Coulter, Fullerton, CA, USA) and counted using a tri carb
TR2100 scintillation counter (Packard, Meriden, CT, USA).
RESULTS
gH2AX foci kinetics were examined in a LCL (control-5; Table 1)
1 h following treatment with graded IR doses up to 4Gy. We found
a clear and roughly linear dose response, consistent with the data
reported by others in this cell type (MacPhail et al, 2003, Figure 1).
We observed six gH2AX foci per nucleus on an average for this cell
line before IR, which is typical for endogenous foci (Vilenchik and
Knudson, 2003). Irradiation with 1, 2 and 4Gy (Figure 1B–D,
respectively) resulted in an average of 22, 41 and 50 foci per
nucleus, respectively, 1 h after IR. A relative decrease in gH2AX
foci number per Gy and an increase in foci overlap was exhibited
at 4 Gy. As doses of 1 and 4Gy tended to be non-linear because of
foci overlap, we used 2Gy for our screening assay, which was
consistent with previous reports that showed 2Gy to be at the
upper end of the linear response range for counting gH2AX foci
using ICC methods (MacPhail et al, 2003).
To confirm the reliability of the ICC assay, we tested LCLs with a
known cellular RS phenotype, namely, LCLs with a ligase IV
homozygous deficiency and also an ATM-deficient cell line. We
found that the ligase IV-deficient cell line had a higher number of
foci when compared with the controls (n¼ 11) at 1 h following IR,
with over 30 gH2AX foci per nucleus after 8 h, much higher than
the number of foci found in controls, indicating a slow repair rate
for these cells (Kuhne et al, 2004) (Figure 2). The ATM-deficient
cell lines did not have any significant differences in foci induction
or depletion as compared with the controls (Figure 2). This is also
consistent with previous findings that, although considerably RS,
ATM-mutated homozygous cell lines repair bulk DNA DSBs with
Table 1 Patient characteristics
Cancer type Cancer site RTOG Dose received Radiosensitivity Sex Age
Controls
1 Adenocarcinoma Prostate 0–1 64/32/5 NA M 70
2 Adenocarcinoma Prostate 0–1 64/32/5 NA M 62
3 IDC Breast 0–1 50/25/5 NA F 60
4 IDC Breast 0–1 46/23/5 NA F 70
5 Adenocarcinoma Prostate 0–1 66/33/5 NA M 82
6 None Nil 0–1 NA NA M 39
7 Adenocarcinoma Breast 0–1 NA NA F 53
8 IDC Breast 0–1 50/25/5 NA F 71
9 IDC Breast 0–1 46/23/5 NA F 47
10 Adenocarcinoma Breast 0–1 46/23/5 NA F 63
11 IDC Breast 0–1 50/25/5 NA F 52
Acute reactors
1 IDC Breast 3 50/25/5 Erythema, oedema F 59
2 SCC Lung 3 36/12/5 Severe dyspnoea M 75
3 IDC Breast 3 18/9/5 Wet desquamation F 44
4 SCC Tonsillar 3 50/25/5 Mucositis M 64
5 SCC Cervical 3 54/30/5 Sigmoid obstruction F 72
6 Melanoma Skin 3 50/25/5 Desquamation F 54
7 Seminoma Testicle 3 16.5/11/4 Severe nausea, diarrhoea M 31
Late reactors
1 Adenocarcinoma Prostate 3 60/30/5 Rectal bleeding M 61
2 IDC Breast 3 46/23/5 Fibrosis F 63
3 Adenocarcinoma Prostate 3 64/32/5 Rectal bleeding, haematuria M 63
4 Adenocarcinoma Prostate 3 64/32/5 Rectal bleeding M 71
5 Adenocarcinoma Prostate 3 66/33/5 Rectal bleeding M 73
6 Adenocarcinoma Prostate 3 64/32/5 Haematuria M 67
7 MC Breast 3 46/23/5 Fibrosis F 51
8 SCC Cervical 3 45/25/5 Sigmoid and ureter stricture F 40
9 LC Breast 3 50/25/5 Fibrosis, telangiectasia F 73
10 Adenocarcinoma Prostate 3 64/32/5 Rectal bleeding M 78
11 LC Lung 3 40/20/5 Pneumonitis, dyspnoea F 69
Abbreviations: F¼ female; IDC¼ infiltrating ductal carcinoma; LC¼ lobular carcinoma; M¼male; MC¼medullary carcinoma; NA¼ not applicable; RTOG¼Radiotherapy
Oncology Group; SCC¼ squamous cell carcinoma.
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similar kinetics to control cells, but have an elevated number of
residual, perhaps complex, DNA DSBs (Kuhne et al, 2004).
We aimed to determine whether there was a link between
clinical RS and the response to radiation as measured by gH2AX
ICC. Therefore, we analysed a relatively large cohort of 18 LCLs
derived from RT patients who showed severe (RTOGX3) adverse
normal tissue RT reactions and 11 non-RS control cancer patients.
Background foci varied between the cell lines, with a range of 4–23
and a median of about 12 foci per nucleus. Treatment with 2Gy of
IR yielded around 35 foci per nucleus on an average within the first
hour (Figure 3). There was a slow decline in visible gH2AX foci,
which resulted in about 20–25 foci per nucleus on an average, after
8 h post-IR (Figure 3). The average rate of gH2AX depletion from
the first hour to 8 h following IR was 2 foci and 1.2 foci per hour
for controls and RSs, respectively. A subset of these samples
(n¼CL-5; RS¼ 13) were analysed at 24 h post-IR and showed a
further decrease in foci number, approximately to background
levels (Figure 3). Statistical analysis revealed no significant
difference between control and RS samples, on average.
Clinical RS can be classified into two main types: acute, wherein
the adverse effects are apparent during or soon after treatment,
and late, wherein the adverse reactions, such as fibrosis, present an
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Figure 1 Dose response of gH2AX focus formation in lymphoblast cell lines (LCLs). Immunocytochemistry (ICC ) was used to capture representative
gH2AX focus images from asynchronous log-phase non-radiosensitive (RS) control cells (control-5) before (A) and 1 h after 1Gy (B), 2 Gy (C) and 4Gy
(D) of ionising radiation (IR). (E) A more detailed view of gH2AX focus distribution, apparently not limited to either euchromatin or heterochromatin in a
cell exposed to 2Gy of IR. Slides were counterstained with DAPI to visualise nuclei (left panels). gH2AX foci were quantified as foci per nucleus for each
dose (F). Error bars are the standard error of the mean (s.e.m.) of gH2AX foci number per nucleus from three separate experiments, wherein at least
100 nuclei cells were scored per dose.
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Figure 2 Time-course kinetics of DNA repair-deficient LCLs. gH2AX
foci per nucleus are shown for controls (n¼ 11; open bars), homozygous
ATM mutant (three experimental replicates; grey bars) and ligase IV knock-
out (three experimental replicates; black bars) human cell lines. gH2AX foci
number was counted in cells before (0 h) and 1 and 8 h after exposure to
2Gy of IR. Error bars represent s.e.m. of gH2AX foci number per nucleus.
Controls
Radiosensitives
H
2A
X 
fo
ci 
pe
r n
uc
le
us
60
40
20
0
Time (hours)
0 0.5 1 4 8 24
Figure 3 Time-course kinetics of IR-induced gH2AX foci in LCLs
derived from clinically RS individuals (n¼ 18) vs control LCLs (n¼ 11).
gH2AX focus number was measured in control (open bars) and RS (filled
bars) cell lines before (0 h) and at various times after 2Gy of IR. Error bars
represent s.e.m. of foci number per nucleus based on 4–5 fields of
approximately 20–25 cells per field. Data have been graphed from 0 to 8 h
for all RS and CL cell lines (controls: n¼ 11; RS: n¼ 18), and at 24 h for
a random subset of cell lines (controls: n¼ 5 [CL1, CL3, CL4, CL9, CL11];
RS: n¼ 13 [A1, A2, A3, A4, A6, A7, L3, L5, L6, L7, L9, L11]) (Table 1).
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adverse phenotype 6 months or longer following radiation
treatment. Therefore, we sub-divided our cell lines into these
two categories for further analysis (Figure 4). One cell line, RS1,
stood out with a relatively slow rate of gH2AX foci depletion after
4, 8 and 24 h. This cell line was subjected to additional testing for
gH2AX foci induction. We confirmed the slow gH2AX foci
depletion for this cell line in two independent experiments
(Figure 5A). The gH2AX foci levels of the RS1 cell line were also
checked at a longer time point (24 h) and found to have 29 foci,
much higher than any of the controls (n¼ 5), which had an
average of 15 foci after 24 h of recovery (Figures 4 and 5). We also
observed that RS1 had higher basal levels of gH2AX foci (Figure 5A
and B), perhaps reflecting genomic instability in this transformed
cell line.
We also wanted to confirm, in an independent DNA DSB repair
assay, the impaired DNA DSB repair phenotype in RS1 cells, and
examined it using PFGE, which directly detects the repair of high-
molecular-weight DNA fragments by quantifying DNA release
from the wells of an agarose gel. Consistent with the gH2AX foci
results, we also found in the RS1 LCLs that there was more residual
DNA fragmentation after various times of recovery, relative to
controls, confirming impaired DNA DSB repair in the cell line
(Figure 5C).
DISCUSSION
The RS patients’ whose cells were studied here were from
phenotypically normal individuals with unexpected severe RT
reactions in their normal tissues; no cases had the stigmata of the
known RS syndromes, involving genes such as ATM, NBS and
BRCA. A subset of the RS cases and controls had previously been
screened for mutations in the BRCA1 and BRCA2 cancer
predisposition/radiation response genes, with no definite muta-
tions being found (Leong et al, 2000).
Our results are consistent with others (Kuhne et al, 2004) in that
we found a clear difference in IR-induced gH2AX foci depletion in
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Figure 5 Dynamics of DNA repair in LCLs from an RS individual (RS1) following IR . (A) gH2AX focus numbers for unirradiated (0 h) cells and irradiated
cells at various time intervals after 2Gy of IR are shown for control cell lines (open bars) and the RS1 cell line from two separate experiments (filled bars).
Error bars represent s.e.m. of foci number per nucleus determined from 11 control cell lines and two replicates of RS1. (B) Representative gH2AX ICC
focus images are shown for asynchronous log-phase RS1 cells before and at the indicated times (hours) after 2Gy of IR . (C) Pulsed-field gel electrophoresis
(PFGE) was carried out on RS1 (filled triangles), and a ligase IV-deficient cell line (filled squares) after various time points (in hours) along with six controls
(open circles; CL1, CL2, CL5, CL9, CL10, CL11) following 40Gy of radiation. Error bars represent the differences in mean from two separate experiments,
each determined from two replicates run on separate gels.
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Figure 4 Time-course kinetics of gH2AX focus induction and repair for
each LCL following IR. gH2AX focus numbers per nucleus before (0 h) and
at various times after 2Gy are plotted for each control cell line (open
squares), acute (filled triangles) and late (filled circles) RS patients. RS1 is
designated as an open triangle.
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a human cell line for which an important gene in DNA repair, DNA
ligase IV, has been knocked out, showing the applicability of these
molecular methods to RS cell lines. However, we observed no
detectable difference between the control group and the RS group
as a whole by following gH2AX foci kinetics after IR. Nevertheless,
we did find one cell line from the group of RS patient-derived cell
lines that showed similar gH2AX kinetics to the ligase IV knockout
cell line, which was confirmed by using a direct DNA damage and
repair assay. We believe that the gH2AX assay has the potential to
perform better than many other cellular RS predictive assays
because it detects a very early event, but is still measurable for a
reasonable period of time following DNA damage. Moreover, DSBs
can be directly correlated with foci, and these can be directly
visualised in situ. Besides, we noted less variability in the RS1 cell
line using the gH2AX assay compared with the PFGE DNA damage
and repair assay. Most investigations of cellular response to
radiation normally use doses that are well above the threshold of
the mean lethal total body dose of 4 Gy in humans. The gH2AX
assay circumvents confounding problems that may be associated
with dose.
We contend that the slow rate of depletion of visible gH2AX foci
in RS1 relative to controls may be because of the factors that led
to the patients’ acute clinical RS. The RS1 patient showed a
particularly striking acute reaction with strong erythema after only
a cumulative 10Gy dose of IR. We presume that both the high
basal foci levels and the DNA repair defect in RS1 are because of
the same defect.
We also observed a large inter-cell line range of gH2AX foci at
the basal level, as well as at different times following IR. This is
consistent with previous reports using the gH2AX assay (Ismail
et al, 2007), as well as with other RS assays. Therefore, the gH2AX
assay used here may not be able to pick up some cell lines with
different types or moderate DNA repair defects because of a
relatively high variance; however, it still may be better than other
common RS assays. It was clearly competent for detecting basal
levels predictive of faulty DNA repair. We determined that the loss
of gH2AX foci occurs with an half-life of approximately 6 h in
control LCLs, but foci levels at this time for the RS1 cell line were
still as high as the control levels at 0.5 h and 1 h following IR, and
had a half life for foci loss that was much slower than that of
controls over the first 8 h.
A number of authors have shown using different assays of
radiation response that Epstein–Barr virus (EBV) transformation
may affect RS. However, alterations to RS have not tended to be
systematic, nor to correlate with EBV load. We previously noted
that (Lovelock et al, 2007):
‘EBV-mediated immortalisation of lymphocytes results in altera-
tions to levels of expression of a number of cell genes, including
several transcription factors. Epstein-Barr Virus Nuclear Antigen-3
(EBNA-3) also disrupts the G2/M cell cycle checkpoint. As part
of the immortalisation process, the normal cellular functions of
lymphocytes are likely to be disruptedy..’.
In an attempt to control one variable in the immortalisation
process, we confirmed by western blot that all LCLs used were
transformed by the same EBNA2A EBV strain (Lovelock et al,
2007). For the clonogenic survival end point, LCL survival may
cluster more than expected compared with non-transformed but
cycling B-cells, which can show a wider spread of response
(Maneerat et al, in preparation). By using the gH2AX assay as we
have shown here, it is unknown whether clustering of data (i.e.,
just one clear outlier) may have been less if non-transformed cells
had been used for the screen. However, the fact that ligase IV
control LCLs were a clear outlier suggests that the assay as
performed can pick up true RS independent of EBV transforma-
tion. Ideally, to resolve these issues, one would like to screen both
immortalised and mortal cells from RS patients using assays that
characterise a number of radiation-response end points. We did
not observe unusually high basal levels of DNA damage in the RS1
cell line using the PFGE DNA damage and repair assay as we did in
the gH2AX assay. This may be because the majority of variations in
basal level breaks observed are due to the shearing caused during
DNA processing, and the true initial DNA DSB levels are probably
too low to be detected using the PFGE assay that uses such high IR
doses. However, RS1 cells had an obvious lag in repair in the PFGE
DNA damage and repair assay, which, even after 4 h, was still
relatively high compared with the average of the controls.
The defect in DNA repair in RS1 may be further explored by
immunofluorescence co-localisation of other repair factors known
to form foci at sites of DNA damage. In addition, expression analysis
and the use of DNA repair protein functional studies will be pursued.
In conclusion, a fraction of patients who are predisposed to
adverse reactions could be detected using ICC assays that detect
gH2AX foci. This application, in combination with other predictive
assessments, may eventually facilitate the tailoring of RT regimes
to individuals, which could result in lesser side effects of RT and
better tumour control.
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